N-(2-diethylamino-ethyl)-4-(4-trifluoromethoxy-benzylamino)-benzamide | 848441-70-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-diethylamino-ethyl)-4-(4-trifluoromethoxy-benzylamino)-benzamide
• 英文别名: N-[2-(diethylamino)ethyl]-4-[[4-(trifluoromethoxy)phenyl]methylamino]benzamide
• CAS: 848441-70-3
• 化学式: C₂₁H₂₆F₃N₃O₂
• 分子量: 409.452
• InChiKey: IHOMCMCIZQAKTG-UHFFFAOYSA-N

物化性质

• 沸点：
  508.9±50.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  对三氟甲氧基苯甲醛 、 盐酸普鲁卡因胺 在 N,N-二异丙基乙胺 、 三乙酰氧基硼氢化钠 作用下， 反应 18.33h， 生成 N-(2-diethylamino-ethyl)-4-(4-trifluoromethoxy-benzylamino)-benzamide
  参考文献：
  名称：

  [EN] SUBSTITUTED ACETANILIDES AND BENZAMIDES FOR THE TREATMENT OF ASTHMA AND PULMONARY INFLAMMATION
  [FR] ACETANILIDES ET BENZAMIDES SUBSTITUES UTILISES DANS LE TRAITEMENT DE L'ASTHME ET DES INFLAMMATIONS PULMONAIRES

  摘要：

  公开号：

  WO2005025498A3

文献信息

• Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
  申请人：Hofmann Thomas

  公开号：US20060062738A1

  公开（公告）日：2006-03-23

  A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.

  一种改善通过吸入给药的有效治疗剂耐受性的方法，包括在给药主要有效治疗剂之前立即或最多三十分钟用雾化利多卡因或利多卡因类化合物对患者进行预处理。用雾化利多卡因或利多卡因类化合物对患者进行预处理可提高气道耐受性和药剂在肺部的沉积，并使这种沉积更加安全、有效、可控和可预测。本发明的方法尤其适用于增强免疫抑制剂在移植患者肺部的沉积，通过减少咳嗽改善药物耐受性，以及改善肺部药物沉积。
• A METHOD FOR IMPROVEMENT OF TOLERANCE FOR THERAPEUTICALLY EFFECTIVE AGENTS DELIVERED BY INHALATION
  申请人：Corus Pharma Inc.

  公开号：EP1807123A2

  公开（公告）日：2007-07-18
• Method For Improvement Of Tolerance For Therapeutically Effective Agents Delivered By Inhalation
  申请人：Hofmann Thomas

  公开号：US20090004279A1

  公开（公告）日：2009-01-01

  A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.
• US7452524B2
  申请人：——

  公开号：US7452524B2

  公开（公告）日：2008-11-18
• US8003081B2
  申请人：——

  公开号：US8003081B2

  公开（公告）日：2011-08-23